Use This Algorithm to Treat Upper GI Malignancies
By Oncology Brothers - Last Updated: January 30, 2023Rutika Mehta, MD, assistant professor of oncology at the Moffitt Cancer Center, discusses treatment options for upper gastrointestinal cancer (including esophageal, esophagogastric junction [GEJ], and gastric cancers) that can be used in practice to inform standard of care in the community oncology setting.
Advertisement
Advertisement
Related Posts
Dr. Cytryn considers two studies evaluating PD-1 inhibition in patients with MSI-high tumors in the locally advanced setting.
Dr. Janjigian reviews KEYNOTE-811, and how it led to the FDA approval of pembrolizumab for HER2-positive gastric cancers.
Of subtypes in KEYNOTE-059 and -061, HRD scores and TMB were highest in CIN and MSI-H subtypes, respectively.
Pembrolizumab previously received accelerated approval for this indication in 2021 based on interim results from KEYNOTE-811.
The safety profile of the combination was consistent with known profiles, and no new safety findings were observed.
630 Madison Ave.
Manalapan, NJ 07726
About Column
Contribute Column
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.